pikfyv
lipid
kinas
involv
endosom
matur
emerg
haploid
genet
screen
requir
ebola
viru
ebov
infect
analyz
effect
apilimod
pikfyv
inhibitor
report
well
toler
human
phase
clinic
trial
effect
entri
infect
ebov
marburg
viru
marv
first
found
apilimod
block
infect
ebov
marv
huh
vero
primari
human
macrophag
cell
notabl
potenc
macrophag
ic
nm
next
observ
similar
dose
apilimod
block
ebovglycoproteinviru
like
particl
vlp
entri
transcriptionrepl
compet
vlp
infect
suggest
primari
mode
action
apilimod
entri
inhibitor
prevent
releas
viral
genom
cytoplasm
initi
replic
provid
evid
antiebov
action
apilimod
via
pikfyv
show
block
traffick
ebov
vlp
endolysosom
contain
niemannpick
intracellular
receptor
ebov
concurr
apilimod
caus
vlp
accumul
earli
endosom
antigen
endosom
detect
effect
apilimod
bulk
endosom
acidif
activ
cathepsin
b
l
cholesterol
export
endolysosom
henc
antagon
pikfyv
apilimod
appear
block
ebov
traffick
site
fusion
entri
cytoplasm
given
drug
observ
antifilovir
activ
rel
unexplor
mechan
entri
inhibit
report
toler
human
propos
apilimod
explor
part
therapeut
regimen
treat
filovir
infect
plo
neglect
tropic
diseas
http
doith
recent
outbreak
ebola
viru
ebov
diseas
western
africa
highlight
urgent
need
develop
therapeut
help
quell
devast
hemorrhag
fever
viru
especi
resourcelimit
area
around
globe
show
apilimod
investig
drug
welltoler
phase
clinic
trial
rheumatoid
arthriti
crohn
diseas
psoriasi
strong
inhibitor
ebov
marburgviru
infect
multipl
cell
type
work
show
apilimod
block
entri
ebov
particl
host
cell
cytoplasm
block
particl
reach
normal
portal
entri
niemannpick
endolysosom
find
consist
ident
molecular
target
apilimod
kinas
product
phosphatidylinositol
requir
proper
matur
late
endocyt
organel
henc
propos
apilimod
explor
reposit
part
therapeut
regimen
help
amelior
sequela
filovir
infect
apilimod
block
filovir
entri
infect
plo
neglect
tropic
diseas
http
doi
drug
screen
method
perform
describ
previous
briefli
vero
huh
cell
seed
plate
densiti
x
cellswel
hmdm
plate
densiti
x
cellswel
h
prior
addit
drug
cell
type
apilimod
block
filovir
entri
infect
plo
neglect
tropic
diseas
http
doiconceptu
jmw
ct
th
sm
ggo
leh
pbj
data
curat
rg
formal
analysi
ean
ab
jd
led
rg
hz
jyl
th
fund
acquisit
jmw
pbj
ct
investig
ean
ab
hz
jyl
jm
whd
th
xx
aw
eh
methodolog
ean
jmw
jd
led
pjm
rg
ckt
cm
ycc
ggo
leh
pbj
th
project
administr
jmw
jd
rsb
ct
th
sm
resourc
jmw
ggo
rsb
leh
pbj
ct
th
sm
softwar
rg
supervis
jmw
ggo
leh
pbj
ct
sm
epidem
ebola
viru
diseas
evd
rage
western
africa
sever
filoviru
diseas
epidem
record
histori
sever
promis
therapeut
antibodi
novel
small
molecul
remain
develop
therapeut
yet
approv
treat
patient
evd
continu
pursuit
antiebola
viru
ebov
therapeut
one
strategi
identifi
approv
drug
show
antiebov
activ
goal
repurpos
antiebov
therapeut
either
alon
part
multicompon
regimen
approv
drug
identifi
block
ebov
infect
inhibit
entri
phase
viral
lifecycl
cell
entri
ebov
complex
process
entail
viru
bind
cell
surfac
attach
factor
intern
macropinocytosi
process
endosom
proteas
transport
endolysosom
contain
niemannpick
intracellular
receptor
ebov
final
ebov
fuse
limit
membran
endolysosom
liber
genom
associ
protein
cytoplasm
begin
replic
essenti
role
ebov
entri
infect
power
illumin
haploid
genet
screen
screen
reveal
gene
product
critic
ebov
entri
includ
mani
involv
endosom
lysosom
biogenesi
matur
one
latter
protein
pikfyv
lipid
kinas
phosphoryl
gener
pi
p
pikfyv
pi
p
known
critic
endosom
matur
apilimod
small
molecul
bind
inhibit
phosphotransferas
activ
pikfyv
drug
develop
suppressor
interleukin
product
test
phase
clinic
trial
treatment
crohn
diseas
psoriasi
rheumatoid
arthriti
although
clinic
benefit
yet
report
apilimod
deem
well
toler
human
chose
test
whether
apilimod
could
inhibit
infect
ebov
marburg
viru
marv
three
reason
first
apilimod
bind
ebov
entri
factor
pikfyv
second
apilimod
emerg
blind
screen
drug
fig
tabl
select
potenti
inhibitor
base
upon
hypothes
drugabl
target
theoret
consider
pathway
possibl
involv
ebov
life
cycl
third
reason
apilimod
well
toler
human
find
apilimod
inhibit
infect
ebov
marv
notabl
effect
primari
human
macrophag
initi
target
filovir
infect
mechanist
studi
reveal
apilimod
block
ebov
entri
cell
cytoplasm
work
pikfyv
effect
block
viral
particl
traffick
endolysosom
site
ebov
fusion
henc
propos
apilimod
explor
part
cocktail
small
molecul
combat
evd
vero
african
green
monkey
kidney
atcc
cell
obtain
american
type
cultur
collect
manassa
va
huh
human
hepatocellular
carcinoma
cell
obtain
dr
hideki
ebihara
nation
institut
allergi
infecti
diseas
niaid
rocki
mountain
laboratori
hamilton
mt
peripher
blood
mononuclear
cell
pbmc
prepar
human
whole
blood
biolog
specialti
corpor
colmar
pa
cat
human
monocytederiv
macrophag
hmdm
gener
peripher
blood
mononuclear
cell
integr
research
facil
irf
immunolog
core
laboratori
describ
previous
hmdm
character
flow
cytometr
analysi
express
major
macrophag
marker
includ
human
leukocyt
antigend
relat
confirm
hmdm
popul
matur
highli
purifi
hek
human
embryon
kidney
atcc
via
univers
virginia
tissu
cultur
facil
grivet
monkey
kidney
gift
dr
xiaowei
zhuang
harvard
univers
cambridg
cell
maintain
growth
medium
high
glucos
dulbecco
modifi
eagl
medium
dmem
supplement
lglutamin
sodium
pyruv
antibioticantimycot
gibco
life
technolog
carlsbad
ca
either
supplement
calf
serum
sc
hyclon
ge
healthcar
bioscienc
pittsburgh
pa
hek
cell
fetal
bovin
serum
fb
seradigm
vwr
intern
radnor
pa
cosmic
calf
serum
cc
hyclon
cell
toremifen
citrat
ca
purchas
sigmaaldrich
st
loui
mo
cat
apilimod
ca
purchas
axon
medchem
groningen
nl
cat
nocodazol
ca
purchas
sigmaaldrich
st
loui
mo
cat
marv
detect
mous
antibodi
marv
protein
cat
ibt
ibt
bioservic
rockvil
md
h
cell
stain
secondari
antibodi
antimous
igg
peroxidas
label
antibodi
cat
kpl
inc
gaithersburg
md
luminesc
detect
use
pico
chemiluminesc
substrat
thermo
fisher
scientif
inc
rockford
il
infinit
pro
plate
reader
tecan
morrisvil
nc
quantit
drug
toxic
black
opaqu
cell
plate
cell
type
mock
infect
viru
treat
drug
dilut
condit
infect
cell
h
cell
viabil
measur
use
celltit
glo
luminesc
cell
viabil
assay
kit
accord
manufactur
protocol
promega
madison
wi
luminesc
read
infinit
pro
plate
reader
follow
background
subtract
inhibit
measur
percent
rel
untreat
infect
cell
nonlinear
regress
analysi
perform
ic
calcul
fit
curv
log
agonist
vs
respons
variabl
slope
constraint
remain
graphpad
softwar
la
jolla
ca
error
bar
doserespons
curv
repres
standard
deviat
three
replic
entri
report
virallik
particl
vlp
bear
gp
yambukumayinga
isol
ebov
prepar
describ
previous
brief
hek
cell
confluent
transfect
cdna
encod
ebov
gp
cell
medium
collect
h
posttransfect
clear
debri
vlp
clear
medium
pellet
sucros
cushion
centrifug
resuspend
hm
buffer
mm
hepe
mm
me
mm
nacl
ph
repellet
final
vlp
pellet
resuspend
start
volum
medium
sucrosehm
total
protein
concentr
vlp
determin
bicinchonin
acid
bca
assay
entryreport
vlp
prepar
assess
western
blot
analys
presenc
gp
well
ebov
titer
hek
cell
confirm
entri
compet
vlp
entri
assay
score
abil
incom
entri
report
vlp
cleav
substrat
preload
target
cell
cytoplasm
occur
vlp
fuse
endosom
assay
perform
describ
previous
brief
hek
cell
cell
seed
per
well
clear
plate
h
post
seed
cell
confluent
treat
indic
concentr
apilimod
axon
medchem
dmso
mock
dilut
optimem
omem
gibco
life
technolog
thermo
fisher
scientif
h
co
incub
vlp
dilut
omem
dmso
concentr
apilimod
bound
cell
spinfect
g
h
h
co
incub
substrat
life
technolog
via
thermofish
scientif
waltham
usa
load
cell
use
mm
probenecid
mp
biomed
via
thermofish
scientif
waltham
usa
hek
cell
respect
cell
incub
overnight
rt
fix
analyz
flow
cytometri
measur
correspond
cell
viabil
x
hek
cell
seed
grown
opaqu
white
plate
treat
vlp
entri
without
addit
vlp
follow
overnight
incub
rt
medium
remov
replac
fresh
medium
per
well
fifti
microlit
per
well
celltiterglo
promega
madison
wi
usa
ad
shake
min
rt
rpm
jitterbug
orbit
shaker
boekel
scientif
via
thermofish
scientif
waltham
usa
plate
incub
rt
min
luminesc
signal
detect
use
biotek
synergi
ht
plate
reader
biotek
winooski
vt
usa
transcriptionreplicationcompet
viruslik
particl
trvlp
prepar
describ
brief
hek
cell
seed
six
well
plate
transfect
h
later
confluent
use
miru
madison
wi
usa
pcaggsnp
pcaggsl
tetracistron
minigenom
plasmid
polymeras
minigenom
plasmid
encod
renilla
luciferas
well
matrix
protein
nucleocapsid
associ
protein
gp
ebov
h
post
transfect
medium
well
replac
ml
fresh
growth
medium
contain
fb
h
transfect
medium
contain
trvlp
harbor
renilla
luciferasecontain
minigenom
harvest
pool
clear
cellular
debri
centrifug
min
g
use
trvlp
assay
describ
trvlp
assay
measur
abil
trvlp
contain
renilla
luciferaseencod
tetracistron
ebov
minigenom
infect
target
cell
pretransfect
plasmid
encod
protein
enhanc
trvlp
entri
adhes
factor
plasmid
support
replic
minigenom
trvlp
enter
target
cell
minigenom
replic
transcrib
lead
renilla
luciferas
report
activ
brief
cell
pretreat
apilimod
axon
medchem
dmso
mock
describ
pretreat
solut
remov
replac
trvlp
dilut
growth
medium
contain
sc
indic
concentr
apilimod
dmso
mock
cell
incub
h
co
incub
medium
replac
fresh
growth
medium
contain
sc
renillaglo
substrat
promega
madison
wi
usa
ad
well
plate
immedi
analyz
glomax
plate
reader
promega
madison
wi
usa
assess
cell
viabil
correspond
sampl
without
trvlp
pretreat
solut
remov
replac
fresh
growth
medium
contain
sc
indic
concentr
apilimod
dmso
mock
cell
incub
h
co
incub
medium
replac
fresh
growth
medium
contain
sc
celltiterglo
promega
ad
well
plate
place
jitterbug
orbit
shaker
rpm
min
rt
plate
incub
rt
min
luminesc
signal
detect
use
synergi
ht
biotek
winooski
vt
usa
plate
reader
cell
seed
glass
bottom
dish
mattek
ashland
coat
fibronectin
sigmaaldrich
st
loui
mo
usa
next
day
cell
confluent
cell
treat
indic
drug
indic
concentr
dilut
growth
medium
contain
cosmic
calf
serum
h
co
incub
acridin
orang
life
technolog
thermofish
scientif
waltham
usa
ad
directli
dish
reach
final
concentr
cell
incub
co
incub
min
wash
time
phosphat
buffer
salin
pb
min
per
wash
cell
imag
medium
live
cell
imag
solut
molecular
probe
cat
thermo
fisher
scientif
waltham
contain
fb
gl
glucos
ad
dish
imag
taken
use
nikon
laser
scan
confoc
unit
attach
nikon
eclips
microscop
na
plan
apochromat
object
nikon
melvil
ny
cell
seed
glass
bottom
dish
mattek
ashland
md
usa
coat
fibronectin
sigmaaldrich
next
day
cell
confluent
cell
treat
indic
drug
indic
concentr
plu
topfluor
cholesterol
avanti
polar
lipid
alabast
al
dilut
serumfre
growth
medium
h
co
incub
follow
incub
cell
gentli
rins
pb
cell
imag
medium
live
cell
imag
solut
molecular
probe
contain
fb
gl
glucos
ad
dish
cell
incub
co
incub
min
imag
taken
use
numer
apertur
na
nikon
plan
apo
total
intern
reflect
fluoresc
oil
immers
object
attach
nikon
eclips
microscop
equip
yokogawa
csu
spinningdisk
confoc
unit
hamamatsu
embt
camera
motor
stage
maintain
nikon
perfect
focu
system
vlp
traffick
experi
perform
cell
essenti
describ
previous
follow
minor
modif
cell
pretreat
apilimod
nocodazol
indic
concentr
dilut
omem
prior
vlp
addit
vlp
bound
cell
spinfect
x
g
h
incub
co
incub
indic
time
cell
fix
wash
next
primari
antibodi
rabbit
abcam
mous
endosom
antigen
bd
bioscienc
san
jose
ca
ad
min
room
temperatur
rt
follow
wash
secondari
antibodi
alexafluor
life
technolog
thermo
fisher
scientif
ad
min
rt
cell
wash
coverslip
mount
overnight
glass
slide
use
prolong
gold
antifad
reagent
life
technolog
thermo
fisher
scientif
coverslip
seal
imag
taken
use
nikon
laser
scan
confoc
unit
attach
nikon
eclips
microscop
plan
apochromat
object
coloc
vlp
red
endosom
marker
green
assess
mander
coeffici
statist
analyz
use
graphpad
prism
normal
data
assess
use
dagostino
pearson
normal
test
signific
normal
distribut
data
determin
ttest
signific
nonnorm
distribut
data
determin
mannwhitney
test
cathepsin
bl
activ
assay
describ
previous
thirtyf
drug
obtain
nation
center
advanc
translat
scienc
ncat
dissolv
dmso
drug
dilut
dmem
life
technolog
thermo
fisher
scientif
supplement
mm
lglutamin
q
life
technolog
thermo
fisher
scientif
uml
penicillin
streptomycin
ps
life
technolog
thermo
fisher
scientif
drug
ad
confluent
vero
cell
drug
cell
incub
co
humidifi
incub
plate
final
concentr
final
volum
dmempsq
fb
life
technolog
thermo
fisher
scientif
cell
return
incub
h
efficaci
studi
dmempsq
contain
tcid
recombin
ebov
express
firefli
luciferas
addit
transcript
unit
genbank
access
number
ad
cell
h
postinocul
supernat
remov
glolysi
buffer
promega
ad
cell
incub
min
rt
afterward
lysat
ad
brightglo
reagent
promega
white
opaqu
well
plate
report
activ
measur
use
glomax
luminomet
cytotox
studi
dmempsq
without
viru
ad
cell
follow
h
preincub
drug
cell
return
incub
h
supernat
remov
celltiterglo
reagent
promega
ad
cell
cell
incub
min
orbit
shaker
rpm
addit
min
without
shake
rt
supernat
transfer
white
opaqu
plate
report
activ
measur
use
glomax
luminomet
promega
ribavirin
final
concentr
mgml
well
dmso
concentr
correspond
dmso
concentr
found
drug
dilut
serv
control
experi
involv
infecti
perform
maximum
contain
laboratori
rocki
mountain
laboratori
nation
institut
health
hamilton
mt
follow
approv
protocol
product
mlvluciferas
luc
pseudoviru
particl
hek
cell
seed
densiti
x
cell
per
cm
plate
next
day
cell
approxim
confluent
media
cell
replac
omem
cell
transfect
ptgluc
pcmvmlvgagpol
encod
ebola
gp
delet
mucin
domain
dilut
omem
per
plate
use
lipofectamin
invitrogen
thermofish
scientif
walthan
dilut
omem
per
plate
post
transfect
ml
antibioticfre
growth
medium
contain
sc
ad
plate
cell
incub
h
co
incub
cell
medium
contain
pseudoviru
collect
pool
clear
cellular
debri
centrifug
x
g
min
clarifi
supernat
contain
pseudoviru
pass
filter
pseudovirus
concentr
highspe
centrifug
sucros
cushion
hm
buffer
hepe
me
nacl
min
x
g
final
pseudoviru
pellet
resuspend
growth
medium
concentr
harvest
supernat
hek
cell
seed
densiti
x
cell
per
well
plate
cell
confluent
h
post
seed
transfect
plasmid
encod
gfppikfyv
pegfpcl
use
transit
transfect
reagent
miru
madison
wi
follow
manufactur
instruct
h
post
transfect
cell
reseed
well
opaqu
white
plate
bd
falcon
thermofish
scientif
waltham
densiti
x
cell
per
well
transfect
confirm
fluoresc
microscopi
h
post
reseed
cell
pretreat
h
apilimod
mlvluciferas
particl
pseudotyp
ebov
ad
cell
presenc
apilimod
infect
allow
proceed
h
cell
wash
pb
overlaid
pb
luciferas
activ
immedi
assay
ad
britelit
plu
perkin
elmer
waltham
read
glomax
plate
reader
promega
madison
wi
usa
follow
manufactur
instruct
first
test
whether
apilimod
block
ebov
infect
cell
cultur
apilimod
block
ebov
infect
huh
liver
cell
vero
kidney
cell
primari
human
monocytederiv
macrophag
hmdm
fig
higher
activ
posit
control
toremifen
citrat
apilimod
also
block
marv
infect
cell
type
fig
higher
activ
posit
control
apilimod
notabl
potent
ic
nm
filovirus
hmdm
fig
tabl
similar
potenc
ic
nm
seen
vero
cell
apilimod
less
potent
ic
nm
huh
cell
fig
fig
tabl
begin
probe
mechan
apilimod
block
ebov
infect
directli
compar
doserespons
profil
block
ebov
entri
replic
use
entri
report
vlp
trvlp
respect
set
vlp
bore
gp
mayinga
isol
ebov
apilimod
block
ebov
particl
entri
fig
replic
fig
similar
doserespons
profil
fig
find
suggest
apilimod
block
entri
phase
filovir
lifecycl
sinc
apilimod
target
pikfyv
sinc
pikfyv
requir
ebov
entri
infect
sinc
apilimod
block
ebov
entri
infect
fig
reason
apilimod
block
ebov
entri
infect
target
pikfyv
test
hypothesi
overexpress
pikfyv
gfppikfyv
compar
dose
respons
need
apilimod
block
ebovgp
mediat
pseudoviru
infect
predict
seen
fig
higher
dose
apilimod
need
achiev
similar
level
inhibit
ebov
gpmediat
infect
gfppikfyv
vs
gfp
express
cell
support
propos
apilimod
block
ebov
entri
infect
pikfyvedepend
pathway
recent
work
shown
ebov
traffic
deep
endocyt
pathway
endolysosom
fusion
entri
therefor
ask
whether
apilimod
prevent
ebov
vlp
reach
endolysosom
use
cell
experi
suitabl
flatter
adher
immunofluoresc
analysi
hek
cell
use
previou
experi
fig
first
demonstr
apilimod
block
ebov
vlp
entri
cell
approxim
dosedepend
effect
hek
cell
fig
given
next
ask
apilimod
block
traffick
ebov
gp
vlp
endolysosom
cell
seen
fig
inde
case
apilimod
block
ebov
vlp
traffick
endolysosom
similar
extent
nocodazol
microtubul
destabil
known
block
traffic
earli
late
endosom
find
present
fig
obtain
allow
vlp
prebound
cell
surfac
enter
cell
min
time
point
chosen
base
extens
prior
analysi
time
cours
ebov
vlp
coloc
endolysosom
entri
cell
assur
apilimod
acceler
vlp
traffick
endolysosom
analyz
coloc
vlp
variou
time
min
cell
treat
treat
apilimod
seen
fig
point
time
cours
vlp
seen
associ
endolysosom
apilimodtr
cell
support
conclus
apilimod
block
traffick
ebov
particl
endolysosom
concomit
decreas
traffick
ebov
gp
vlp
endolysosom
apilimod
caus
ebov
vlp
accumul
endosom
fig
apilimodtr
cell
endosom
appear
larger
mocktreat
cell
consist
previou
report
show
enlarg
endosom
cell
genet
defici
pikfyv
treat
pikfyv
inhibitor
find
present
fig
indic
primari
mechan
apilimod
block
ebov
entri
infect
fig
block
viru
transport
earli
endosom
site
fusion
endolysosom
test
model
ask
whether
apilimod
affect
attribut
endosom
pathway
need
ebov
entri
either
endosom
acidif
activ
cathepsin
b
l
concentr
strongli
block
ebov
entri
infect
apilimod
detect
effect
endosom
acidif
fig
bafilomycin
inhibitor
ebov
infect
block
endosom
acidif
use
posit
control
apilimod
also
appar
direct
effect
activ
cathepsin
b
l
fig
contrast
est
known
inhibitor
cathepsin
b
h
l
sever
cation
amphiphil
drug
block
ebov
entri
infect
induc
cholesterol
accumul
endolysosom
contrast
apilimod
caus
detect
increas
cholesterol
level
endolysosom
fig
henc
apilimod
appear
block
filovir
entri
infect
inhibit
viru
particl
traffick
endolysosom
portal
entri
ebov
genom
host
cell
cytoplasm
tragic
demonstr
recent
epidem
evd
western
africa
press
need
remain
develop
therapeut
treat
patient
infect
filovirus
novel
monoclon
antibodi
small
molecul
therapeut
pipelin
parallel
approach
consid
reposit
approv
drug
drug
proven
safe
phase
clinic
trial
treat
evd
studi
test
potenti
util
apilimod
antifilovir
agent
evalu
drug
three
reason
apilimod
directli
target
pikfyv
known
ebov
entri
factor
b
apilimod
emerg
blind
screen
drug
target
cell
signal
pathway
fig
tabl
c
apilimod
report
well
toler
human
sever
phase
clinic
trial
demonstr
apilimod
activ
ebov
marv
sever
cell
type
notabl
human
macrophag
fig
tabl
demonstr
work
pikfyv
primari
mode
action
block
traffick
ebov
particl
endolysosom
fig
site
ebov
fusion
entri
pikfyv
might
particip
ebov
entri
ebov
journey
deep
cellular
endosom
system
enter
cytoplasm
endolysosom
posit
twopor
channel
addit
intracellular
receptor
ebov
requir
multipl
factor
involv
endosom
lysosom
biogenesi
matur
entri
one
latter
factor
pikfyv
phosphoryl
gener
pi
p
shown
apilimod
bind
pikfyv
block
ebov
entri
infect
pikfyvedepend
manner
inhibitori
effect
apilimod
ebov
entri
like
due
defect
matur
endolysosom
extens
evid
indic
import
pikfyv
pi
p
process
although
exact
mechan
pikfyv
pi
p
orchestr
endosom
matur
known
sever
mechan
postul
consid
mechan
observ
two
ca
channel
found
endo
lysosomestransi
receptor
potenti
cation
channel
mucolipin
downstream
effector
pikfyv
pi
p
action
pikfyv
shown
regul
fission
consequ
remodel
matur
reduc
size
macropinosom
contain
endocytos
materi
cell
surfac
exterior
addit
channel
report
activ
pi
p
intriguingli
macropinocytosi
involv
ebov
entri
infect
although
yet
know
endolysosom
factor
need
trigger
ebov
gp
fusion
appear
clear
proper
endosom
matur
requir
find
consist
mount
evid
role
pikfyv
ebov
entri
observ
pikfyv
inhibitor
apilimod
block
transport
ebov
particl
endolysosom
therefor
like
interconnect
effect
apilimod
pikfyv
endolysosom
matur
culmin
blockad
ebov
entri
infect
sever
approv
drug
function
ebov
entri
inhibitor
eg
clomiphen
toremifen
sertralin
block
ebov
entri
cytoplasm
ebov
particl
deliv
endolysosom
henc
like
interfer
aspect
virusendolysosom
membran
fusion
process
per
se
approv
drug
includ
chloroquin
niclosamid
atovaquon
amodiaquin
quinacrin
block
endosom
acidif
henc
drug
like
interfer
process
ebov
gp
acidoptim
endosom
cathepsin
andor
low
phinduc
conform
chang
requir
fusion
activ
cleav
gp
contrast
mechan
find
indic
apilimod
block
ebov
entri
block
particl
deliveri
endolysosom
approv
drug
know
antiebov
activ
expect
mode
action
microtubuledisrupt
agent
includ
colchicin
nocodazol
vinblastin
vinorelbin
henc
mode
action
apilimod
antifilovir
agent
novel
rather
block
ebov
traffick
endosom
interf
microtubul
apilimod
block
ebov
traffick
inhibit
pikfyv
find
indic
apilimod
similar
antivir
activ
ebov
marv
consist
need
endolysosom
entri
filovirus
therefor
consid
like
apilimod
hostdirect
small
molecul
broad
even
panfilovir
activ
furthermor
sinc
mani
virus
socal
late
penetr
virus
traffic
beyond
earli
endosom
entri
possibl
apilimod
block
entri
infect
member
viru
famili
apilimod
investig
drug
although
test
phase
clinic
trial
treatment
crohn
diseas
psoriasi
rheumatoid
arthriti
drug
yet
approv
indic
nonetheless
apilimod
welltoler
human
report
phase
trial
found
intraperiton
deliveri
mgkg
apilimod
mice
result
c
max
well
ic
apilimod
inhibit
ebov
infect
three
cell
line
test
time
greater
ic
hmdm
nm
initi
major
target
filovir
infect
therefor
consid
plausibl
apilimod
use
treatment
evd
apilimod
may
function
singl
agent
may
perform
well
compon
antifilovir
small
molecul
cocktail
summari
introduc
apilimod
small
molecul
pikfyv
inhibitor
proven
safe
phase
clinic
trial
potenti
antifilovir
agent
vero
cell
pretreat
h
compound
indic
concentr
cell
infect
reporterexpress
ebola
viru
presenc
compound
later
report
activ
shown
log
scale
measur
parallel
cell
viabil
determin
drugtreat
noninfect
cell
use
commerci
cell
viabil
assay
viabil
untreat
cell
set
posit
control
ribavirin
use
concentr
mgml
dmso
serv
neg
control
mock
indic
noninfect
untreat
cell
mean
standard
deviat
biolog
replic
shown
tif
tabl
compound
blindli
screen
infect
assay
fig
indic
screen
code
ncgc
number
name
attribut
mechan
action
compound
screen
apilimod
code
identifi
apilimod
fig
